Axsome Therapeutics’ (AXSM) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report sent to investors on Monday,Benzinga reports. They currently have a $133.00 price target on the stock.

A number of other research analysts have also weighed in on AXSM. Robert W. Baird lifted their price target on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. HC Wainwright raised their target price on shares of Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Royal Bank of Canada reissued an “outperform” rating and set a $139.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, January 29th. Truist Financial raised their price objective on Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $121.00 target price on shares of Axsome Therapeutics in a report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $147.13.

Axsome Therapeutics Stock Down 0.5 %

Shares of NASDAQ:AXSM opened at $131.55 on Monday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The stock has a market cap of $6.37 billion, a price-to-earnings ratio of -20.15 and a beta of 1.05. The company has a 50 day moving average of $96.55 and a 200-day moving average of $92.67. Axsome Therapeutics has a one year low of $64.11 and a one year high of $134.18.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million during the quarter, compared to analysts’ expectations of $98.71 million. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. During the same period in the prior year, the business posted ($1.32) EPS. On average, sell-side analysts forecast that Axsome Therapeutics will post -4.7 earnings per share for the current year.

Institutional Trading of Axsome Therapeutics

Large investors have recently made changes to their positions in the company. Northwestern Mutual Wealth Management Co. bought a new position in shares of Axsome Therapeutics in the 2nd quarter valued at $27,000. Assetmark Inc. acquired a new stake in Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd bought a new position in Axsome Therapeutics in the fourth quarter valued at about $64,000. KBC Group NV raised its stake in Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after acquiring an additional 385 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after acquiring an additional 318 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.